Free Trial
OTCMKTS:ACUR

Acura Pharmaceuticals (ACUR) Stock Price, News & Analysis

Acura Pharmaceuticals logo
$0.0004 0.00 (0.00%)
As of 10/6/2025

About Acura Pharmaceuticals Stock (OTCMKTS:ACUR)

Advanced

Key Stats

Today's Range
$0.0004
$0.0004
50-Day Range
N/A
52-Week Range
$0.00
$0.75
Volume
N/A
Average Volume
3,501 shs
Market Capitalization
$26.60 thousand
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive ACUR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Acura Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ACUR Stock News Headlines

Tilson: “I’m watching HOOD”
A strange chasm is coming to Wall Street... It's already creating millionaires and billionaires at the fastest pace in history. CNBC calls it "the largest wealth creation spree in history." Yet 1 in 3 Americans now fear their financial situation is deteriorating. There's only one way to survive, says the man who predicted 2008 and 2020, but sadly it's already too late for many.tc pixel
Acura Pharma Stock Price History - Investing.com
Acura Pharmaceuticals, Inc. (ACUR) - Yahoo Finance
See More Headlines

ACUR Stock Analysis - Frequently Asked Questions

Acura Pharmaceuticals' stock was trading at $0.0002 at the start of the year. Since then, ACUR shares have increased by 100.0% and is now trading at $0.0004.

Acura Pharmaceuticals, Inc. (OTCMKTS:ACUR) announced its quarterly earnings data on Friday, February, 28th. The specialty pharmaceutical company reported $0.00 EPS for the quarter. The specialty pharmaceutical company had revenue of $1.32 million for the quarter.

Acura Pharmaceuticals subsidiaries include Acura Pharmaceutical Technologies Inc..

Shares of ACUR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Acura Pharmaceuticals investors own include Denali Therapeutics (DNLI), Ekso Bionics (EKSO), Matinas Biopharma (MTNB), VIVUS (VVUS), Corbus Pharmaceuticals (CRBP), Fulcrum Therapeutics (FULC) and Adamis Pharmaceuticals (ADMP).

Company Calendar

Last Earnings
2/28/2020
Today
10/07/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
MED - GENERIC DRG
Sub-Industry
Pharmaceuticals
Current Symbol
OTCMKTS:ACUR
Previous Symbol
NASDAQ:ACUR
CIK
786947
Employees
10
Year Founded
1935

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
66,500,000
Free Float
53,066,000
Market Cap
$26.60 thousand
Optionable
Not Optionable
Beta
-2.44

Social Links

7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

This page (OTCMKTS:ACUR) was last updated on 10/7/2025 by MarketBeat.com Staff
From Our Partners